The earliest studies on omicron are in and the glimpse they’re providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters.
Studies from South Africa and Sweden are showing that omicron does, as feared, cause a loss of immune protection — but not a complete one. In a study of blood plasma from people given two doses of the Pfizer-BioNTech shot, there was a 41-fold drop in levels of virus-blocking antibodies compared with the strain circulating at the start of the pandemic.
A separate study from Stockholm’s Karolinska Institute was more optimistic, finding the decline in antibodies against omicron was only slightly worse than for delta, the strain currently causing most Covid-19 cases worldwide.
The earliest studies on omicron are in. While vaccines like the one made by Pfizer and BioNTech may be less powerful against the new variant, protection can be fortified with boosters https://t.co/WpU1iiZ4Mt
— Bloomberg (@business) December 8, 2021